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Variable frequency of LRRK2 variants in the Latin American
research consortium on the genetics of Parkinson’s disease
(LARGE-PD), a case of ancestry
Mario Cornejo-Olivas1,2, Luis Torres3,4, Mario R. Velit-Salazar1,5, Miguel Inca-Martinez1, Pilar Mazzetti1,4, Carlos Cosentino3,4,
Federico Micheli6, Claudia Perandones6, Elena Dieguez7, Victor Raggio8, Vitor Tumas9, Vanderci Borges10, Henrique B. Ferraz 10,
Carlos R. M. Rieder 11, Artur Shumacher-Schuh11, Carlos Velez-Pardo12, Marlene Jimenez-Del-Rio12, Francisco Lopera12,
Jorge Chang-Castello13, Brennie Andreé-Munoz14, Sarah Waldherr15,16, Dora Yearout15,16, Cyrus P. Zabetian15,16 and Ignacio F. Mata15,16
Mutations in Leucine Repeat Rich Kinase 2 (LRRK2), primarily located in codons G2019 and R1441, represent the most common
genetic cause of Parkinson’s disease in European-derived populations. However, little is known about the frequency of these
mutations in Latin American populations. In addition, a prior study suggested that a LRRK2 polymorphism (p.Q1111H) specific to
Latino and Amerindian populations might be a risk factor for Parkinson’s disease, but this finding requires replication. We screened
1734 Parkinson’s disease patients and 1097 controls enrolled in the Latin American Research Consortium on the Genetics of
Parkinson’s disease (LARGE-PD), which includes sites in Argentina, Brazil, Colombia, Ecuador, Peru, and Uruguay. Genotypes were
determined by TaqMan assay (p.G2019S and p.Q1111H) or by sequencing of exon 31 (p.R1441C/G/H/S). Admixture proportion was
determined using a panel of 29 ancestry informative markers. We identified a total of 29 Parkinson’s disease patients (1.7%) who
carried p.G2019S and the frequency ranged from 0.2% in Peru to 4.2% in Uruguay. Only two Parkinson’s disease patients carried p.
R1441G and one patient carried p.R1441C. There was no significant difference in the frequency of p.Q1111H in patients (3.8%)
compared to controls (3.1%; OR 1.02, p = 0.873). The frequency of LRRK2-p.G2019S varied greatly between different Latin American
countries and was directly correlated with the amount of European ancestry observed. p.R1441G is rare in Latin America despite the
large genetic contribution made by settlers from Spain, where the mutation is relatively common.
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INTRODUCTION
Mutations in Leucine Repeat Rich Kinase 2 (LRRK2) represent the
most frequent genetic cause of Parkinson’s disease (PD); there is
consistent evidence that at least eight missense variants (p.
N1437H, p.R1441C, p.R1441G, p.R1441H, p.R1441S, p.Y1699C, p.
G2019S, and p.I2020T) are pathogenic while more than fifty
remain of undetermined significance.1, 2 p.G2019S is the most
frequent pathogenic LRRK2 variant in European-derived, Ashke-
nazi Jewish, and North African populations, however frequencies
range from 0 to 42% worldwide depending on the population.3
While most carriers share a common founder,4, 5 a small group of
patients in Europe and Japan share two different haplotypes,
suggesting at least three different mutation events.6, 7 Another
mutation, p.R1441G, is almost exclusively restricted to Northern
Spain and is thought to have originated in the “Basque” region
during the seventh century.8, 9 Only four patients have been
reported to carry this variant outside of Spain: one in Mexico,10
one in the US,11 one in Uruguay12 and more recently one in
Japan.13 Three other less common pathogenic variants (p.R1441C,
p.R1441H, and p.R1441S) are known to occur within the same
codon.4, 14, 15 Thus p.G2019S, together with variants in the R1441
codon, represent the two largest mutational hotspots in the gene
with highly variable frequencies depending on geographic
location and ethnic background. There are other variants in LRRK2
that are population specific and associated with PD risk such as
the p.G2385R and p.R1628P single nucleotide polymorphisms
(SNPs) in Asians.16
Little is known about the frequency of these or other LRRK2
variants in Latin American countries. In prior studies of small
cohorts from South America our group and others have shown
that the frequency of p.G2019S and p.R1441G varies substantially
across different countries.3, 12, 17, 18 In a small pilot study we also
observed that the LRRK2-p.Q1111H SNP, which is common in
some Latin American populations, occurred at an increased
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frequency in PD patients, though the difference was not quite
significant.19 Thus, whether this variant represents a PD risk factor
in Latino populations remains unclear.
In this study we sought to further elucidate the frequency of the
LRRK2-p.R1441G/C/H/S and p.G2019S mutations and the influence
of p.Q1111H on disease risk in the largest cohort of Latin American
PD patients ever examined.
RESULTS
We identified a total of 29 patients who carried p.G2019S,
including one homozygote (from Argentina). p.G2019S frequency
varied substantially between sites, and was strongly correlated
with the proportion of European admixture observed in repre-
sentative samples from the corresponding site (Table 1; Fig. 1a). All
but two of the carriers had an age at onset over 40 years old
(mean 54.7, range 37–72). All carriers reported at least one
European ancestor, and only five reported a family history of PD.
No sex differences were observed as exactly 50% were females.
Nine unaffected relatives of four of the carriers were also found to
harbor p.G2019S. Their ages ranged from 19 to 55 years old. Five
healthy controls (age at recruitment 39–77) were also found to
carry p.G2019S.
Genotyping of rs28903073 showed that all 34 p.G2019S carriers
(29 patients and 5 controls) carried at least one copy of the minor
allele (A), thus suggesting that they all share the most common
haplotype reported among individuals with p.G2019S in Europe
and North America.4
We also identified three patients who were heterozygous for a
pathogenic mutation in codon 1441. Two carried p.R1441G (from
Uruguay and Peru) and one carried p.R1441C. All three had an age
at onset ≤50 years old. Only the p.R1441C carrier reported a family
history of PD (Fig. 2b), despite the fact that mutations in this
codon are highly penetrant.20, 21 We screened five additional
unaffected family members of the Peruvian patient with p.R1441G,
including both of his parents who are still alive in their late 80s,
and identified three more carriers (Fig. 2a). All carriers from this
family shared the same haplotype that has been reported among
p.R1441G carriers in the “Basque” region (Supplementary Table 1).
We did not find other pathogenic variants in exon 31 for any
patients or controls.
We also screened our cohort for the p.Q1111H polymorphism
and found 118 patients (10 homozygotes) and 58 healthy controls
(3 homozygotes) who carried this variant. The allele frequency was
highly variable between sites and was highly correlated with the
proportion of Amerindian admixture observed at each site
(Fig. 1b). However, there was no significant difference in
p.Q1111H frequency between cases and controls in the combined
sample (or by site) after adjusting for age, sex and site (Table 2).
DISCUSSION
Our findings indicate that the frequencies of the LRRK2 p.G2019S
and p.R1441G/C mutations vary widely across countries in Latin
America, and are strongly linked to the amount of European
admixture existent in each country. We observed a high p.G2019S
frequency in Argentina (3.2%) and Uruguay (4.2%), the two
countries with the highest proportion of European admixture
(>85%). In contrast, the prevalence of the mutation was lower in
Peru (0.2%), where European admixture is only about 25%.
Frequencies in Ecuador (1.2%), Colombia (1.5%) and Brazil (1.4%)
are similar to those observed in other studies in Latin America and
in the US.3 This is the first time that the p.G2019S has been
reported in Ecuador.
Our data indicate that all of the individuals in our sample
carrying p.G2019S share the haplotype most commonly reported
among carriers of this mutation in European-derived, Ashkenazi
Jewish, and North African populations. These individuals are all T
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believed to share a common founder who lived more than 2000
years ago in the Middle East.4
In contrast to the widespread distribution of p.G2019S,
mutations in codon 1441, a mutational hotspot region of the
LRRK2 gene, are rare in Latin America. We only identified three
carriers, two with p.R1441G and one with p.R1441C. It is
interesting that neither of the p.R1441G carriers reported family
history of the disease despite the fact that high penetrance rates
have been reported for this mutation; 83.4% by the age of 80
years.20 The p.R1441G carrier from Peru presented with clinically
typical PD at the age of 29, which is more than two decades lower
than the mean age of onset reported for patients with p.R1441G in
other cohorts.22, 23 In contrast, his 89 year old mother and 54 year
old brother both carry the mutation which have not shown signs
of parkinsonism on serial neurological examinations, demonstrat-
ing that penetrance for this mutation can be highly variable. The
clinical features of the proband were characterized by gradual
progression over two decades, and good response to levodopa
with late onset of motor fluctuations. This is consistent with the
more benign phenotype previously reported in other PD patients
with p.R1441G.24, 25 The reason for the unusually early age at
onset of the proband is not clear.21 He was negative for both point
and dosage mutations in the PARK2 gene (data not shown), the
most frequent genetic cause of early-onset PD, as well as for
mutations in GBA which not only increase risk for PD but also
lower the age at onset by at least 4 years.26 It is possible that
environmental exposures or other genetic factors not tested
might influence the age at onset in this instance. All of the carriers
in this family share the common haplotype which is thought to
have originated in the Basque region during the VII century. This
agrees with the historic influence of Spanish colonizers in the
Peruvian population.27, 28
The other p.1441G carrier has been previously described
elsewhere.12 The low p.R1441G frequency in our sample is
somewhat surprising due to the large historical influence of Spain
in Latin America. However this is consistent with previous smaller
studies in which no carriers were found including patients from
Brazil29 and Chile.30 This low frequency might be explained by
many factors including the possibility that the first Spanish
colonizers came from regions in Spain with a low mutation
frequency. Including our carriers, only five have been identified
outside of Spain.10–13 Regarding the other cases outside of Spain,
the Uruguayan and Japanese p.R1441G PD cases showed a novel
haplotype suggesting a distinct founder effect,12, 13 while for the
Mexican and North American cases no haplotype analysis was
reported.10, 11
We also identified a patient carrying p.R1441C, which we
believe is the first report of this mutation in South America. Most
of the families previously reported with this mutation are from
Europe or the US, except for one from Asia. At least four different
haplotypes have been observed in individuals with p.R1441C.31
Our patient reported that his paternal relatives originated in Spain,
while his maternal relatives came from Lebanon.
The proband of our p.R1441C family was a 63 year old male
who presented with bradykinesia and rigidity in the right upper
limb at the age of 44 years. He was started on levodopa therapy
3 years later with a clear symptomatic response. He has never
displayed a resting tremor, but does have a slight bilateral postural
tremor. These clinical characteristics are somewhat atypical
because nearly 60% of patients with p.R1441C report resting
tremor, as their initial symptom and <20% of carriers have an age
at onset of <50 years.21, 31 The proband developed motor
complications after 3 years of levodopa treatment, and now has a
very short duration of drug action (90–120min) and moderate
peak-dose dyskinesias with generalized choreic and dystonic
movements. He is in Hoehn and Yahr stage III, when in the “on
state”. No significant cognitive impairment was observed on
detailed neuropsychological testing at age 59. He reported nine
relatives affected with parkinsonism, however DNA was not
available for additional individuals of the family (Fig. 2).
Finally, LRRK2 p.Q1111H was originally reported in two siblings
with PD from the U.S., but the pedigree was too small to assess
segregation.32 However this variant was nominated as potentially
pathogenic since it was not found in almost 400 non-Hispanic
white controls. We later demonstrated that p.Q1111H is a
common variant that is restricted to populations of Amerindian
origin.19 In an analysis of 1150 PD patients and 310 healthy
controls from Peru and Chile we showed a trend toward an
association between p.Q1111H and PD (OR 1.38; p = 0.10). Here we
attempted to validate these findings in the largest Latin American
PD cohort ever assembled. However, after adjusting for important
covariates we observed no association between p.Q1111H and PD
(OR 1.02, p = 0.873). This suggests that p.Q1111H is a “benign”
population specific SNP.
Human genetics is proving to be a key component of
personalized medicine. However, most PD genetic studies have
focused on individuals of European origin, and little is known
about genetic risk factors and causal genes for PD in other
populations. Without such information, it will be difficult to
individualize new treatments for PD patients from underrepre-
sented groups, which might further increase existing social
disparities. Furthermore, genetic analyses of non-European
populations might yield new PD genes that could elucidate novel
therapeutic targets to benefit all patients. The data presented here
begin to address this gap in knowledge, and we have just initiated
large scale studies in the LARGE-PD cohort that will further define
the genetic profile of PD in Latinos.
A
B
r2 = 0.98
r2 = 0.84
Fig. 1 Correlation between frequency of a p.G2019S and b p.
Q1111H carriers and the proportion of European or Amerindian
admixture in the cohort from each site. Correlation is shown in each
of the figures as the coefficient of determination (r2)
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MATERIALS AND METHODS
Subjects
We screened a total of 1734 PD patients and 1097 healthy controls
recruited in Argentina, Brazil, Colombia, Ecuador, Peru, and Uruguay as part
of the Latin American Research Consortium on the Genetics of Parkinson’s
disease (LARGE-PD). All patients were evaluated by a movement disorders
specialist at each of the sites and met UK PD Society Brain Bank clinical
diagnostic criteria. The characteristics of this cohort are presented in
Table 1. Data for a subset of these subjects has been previously published
in analyses of p.G2019S and codon 1441 mutations (n = 365), and for
p.Q1111H (n = 940).12, 19
Genetics
Genomic DNA was extracted from peripheral blood samples using
standard methods. All samples were screened for p.G2019S and p.
Q1111H by TaqMan assay and a cluster of four substitutions in codon 1441
(p.R1441C/G/H/S) by sequencing LRRK2 exon 31 using the Applied
Biosystems Big-Dye Terminator v3.1 Cycle Sequencing Kit. Sequence data
were analyzed using Mutation Surveyor (SoftGenetics, PA). All p.G2019S
carriers were verified by Sanger sequencing using the same methods as
for exon 31.
Haplotype analyses for p.R1441G were performed using 5 SNPs and
10 microsatellite markers spanning 6 Mb across the LRRK2 region28
(Supplementary Table 1). The haplotype background for
p.G2019S was determined by genotyping rs28903073. The “A” allele for
this SNP has a frequency of <0.1% and if observed indicates the presence
of the rare haplotype shared by most p.G2019S carriers.4
SNP markers were genotyped by Sanger sequencing using previously
described methods.9 Microsatellites were amplified by PCR using
fluorescently labeled Forward primers, run on an ABI PRISM 3130
Genetic Analyzer, and analyzed using GeneMapper 4.0 software (Applied
Biosystems, CA).
We also screened a total of 214 individuals from five of the six
participating sites (range, 17–50) using a custom panel of 29 ancestry
informative markers (AIMs) to estimate the proportion of admixture for the
four continental population groups (Asian, African, European, and
Amerindian) present in each site (Supplementary Methods and Supple-
mentary Tables 2 and 3). Genotyping was performed using TaqMan assays
on the Fluidigm BioMark HD System. We used STRUCTURE (http://pritch.
bsd.uchicago.edu/structure.html) to estimate the percent ancestry for our
samples with reference to the HDGP + HapMap Phase III groups.
Statistical analysis
Association of PD with p.Q1111H was assessed by logistic regression
analysis under an additive model, adjusting for sex and age. We also
included site as a covariate in the analysis of the combined cohort.
Fig. 2 Pedigree diagram of the a Peruvian p.R1441G and b Brazilian p.R1441C families. Individuals affected with Parkinson’s disease are
represented with black symbols, unaffected individuals with open symbols. Age at last clinical evaluation (or age at death if individual is
deceased) is indicated immediately below each symbol, followed by age at onset; +, mutation carrier; wt, wild-type
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Analyses were performed using Stata software (version 14.0; StataCorp LP,
College Station, TX).
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